 |
Top 19 CAR-T startups in USA
Sep 30, 2025 | By Jason Kwon | 25 |
1
Funding: $172M
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
2
Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
3
Funding: $1B
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
4
Funding: $460.5M
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
5
Funding: $369.5M
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
6
Funding: $363M
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
7
Funding: $340M
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
8
Funding: $337M
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
9
Funding: $256M
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
10
Funding: $216M
Dispatch Bio was formed around the concept of solving two obstacles in cancer care: developing a treatment that can differentiate cancer cells from healthy cells while also addressing resistance mechanisms.
Dispatch Bio was formed around the concept of solving two obstacles in cancer care: developing a treatment that can differentiate cancer cells from healthy cells while also addressing resistance mechanisms.
11
Funding: $210M
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
12
Funding: $198M
Artiva Biotherapeutics is an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Artiva Biotherapeutics is an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
13
Funding: $168M
Modex Therapeutics's modular platforms unite the power of multiple biologics into single molecules to combat complex diseases. The current focus is on cancer and infectious disease, where multispecifics hold great promise to address the diverse antigens and immune evasion that are responsible for the vast majority of patient deaths.
Modex Therapeutics's modular platforms unite the power of multiple biologics into single molecules to combat complex diseases. The current focus is on cancer and infectious disease, where multispecifics hold great promise to address the diverse antigens and immune evasion that are responsible for the vast majority of patient deaths.
14
Funding: $112M
AvenCell Therapeutics develops next generation immunotherapies for hard-to-treat cancers.
AvenCell Therapeutics develops next generation immunotherapies for hard-to-treat cancers.
15
Funding: $100M
Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
16
Funding: $88.2M
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
17
Funding: $87.6M
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
18
Funding: $63M
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases. It produces cancer-specific natural killer (NK) cells that are developing while suspended in a liquid solution within a bioreactor, allowing them to reproduce indefinitely.
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases. It produces cancer-specific natural killer (NK) cells that are developing while suspended in a liquid solution within a bioreactor, allowing them to reproduce indefinitely.
19
Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
★
See also:
